D. G. Konkov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
D. G. Konkov has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- O. V. Bulavenko
Vinnytsia National Pirogov Memorial Medical University, Vinnytsia
10 shared publications - Оксана Анатоліївна Таран
National Pirogov Memorial Medical University, Vinnytsya, Ukraine
6 shared publications - V.O. Rud
Вінницький національний медичний університет імені М.І. Пирогова
5 shared publications - V. V. Klivak
Вінницький НМУ ім. М.І. Пирогова, м. Вінниця
4 shared publications - Anzhelika V. Starovier
Vinnytsia National Pirogov Medical University, Vinnytsia
3 shared publications - O. A. Muntyan
Vinnytsia National Pirogov Medical University, Vinnytsia
3 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 85,p. 37-50
Clinical efficacy and biological rationale of adjunctive distrept-enzymes H46A streptokinase-streptodornase therapy in gynecology: a systematic review with quantitative synthesis
Objective of the study: to systematically evaluate the efficacy and safety of adjunctive distrept-enzymes H46A streptokinase-streptodornase therapy in women with gynecological disorders and to interpret the available clinical evidence within the context of current concepts of inflammation, fibrinolysis, extracellular DNA, immunothrombosis, and adhesion biology.Materials and methods. PubMed, Embase, CENTRAL, Scopus, Web of Science, Europe PMC, ClinicalTrials.gov and additional sources were systematically searched from database inception through 2026 without language restrictions. The review followed PRISMA 2020 recommendations and was prospectively designed according to Cochrane methodology.Randomized controlled trials evaluating distrept-enzymes H46A streptokinase-streptodornase therapy in women with postoperative gynecological complications, pelvic inflammatory disorders, endometriosis-associated symptoms or related reproductive conditions were eligible. Primary outcomes included postoperative recovery, inflammatory resolution, pelvic pain, adhesion-related outcomes and reproductive preservation.Results. The review demonstrated consistent clinical improvements associated with adjunctive distrept-enzymes H46A streptokinase-streptodornase therapy across multiple gynecological settings. Compared with standard management alone, enzymatic therapy was associated with higher rates of complete hematoma resolution, greater reductions in C-reactive protein concentrations, faster functional recovery, improved quality of life, and clinically meaningful reductions in pelvic pain. Improvements in dyspareunia, dysuria and dyschezia were also observed among women with endometriosis-associated symptoms. No evidence suggested an increased frequency of serious adverse events, clinically significant bleeding or treatment discontinuation attributable to therapy. Formal pooled meta-analysis, estimation of between-study heterogeneity and prediction intervals were not appropriate because each outcome was represented by only one independent comparative study.Conclusions. The currently available randomized evidence suggests that distrept-enzymes H46A streptokinase-streptodornase therapy may accelerate postoperative recovery and resolution of pelvic inflammatory disease while supporting preservation of reproductive anatomy and function. Contemporary understanding of fibrinolysis, extracellular DNA, and immunothrombosis provides a strong biological rationale for these clinical observations. Nevertheless, the certainty of evidence remains limited by the small number of independent randomized studies, underscoring the need for multicenter trials.
- 30 September 2026
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 85,p. 37-50
Open AccessClinical efficacy and biological rationale of adjunctive distrept-enzymes H46A streptokinase-streptodornase therapy in gynecology: a systematic review with quantitative synthesis
Objective of the study: to systematically evaluate the efficacy and safety of adjunctive distrept-enzymes H46A streptokinase-streptodornase therapy in women with gynecological disorders and to interpret the available clinical evidence within the context of current concepts of inflammation, fibrinolysis, extracellular DNA, immunothrombosis, and adhesion biology.Materials and methods. PubMed, Embase, CENTRAL, Scopus, Web of Science, Europe PMC, ClinicalTrials.gov and additional sources were systematically searched from database inception through 2026 without language restrictions. The review followed PRISMA 2020 recommendations and was prospectively designed according to Cochrane methodology.Randomized controlled trials evaluating distrept-enzymes H46A streptokinase-streptodornase therapy in women with postoperative gynecological complications, pelvic inflammatory disorders, endometriosis-associated symptoms or related reproductive conditions were eligible. Primary outcomes included postoperative recovery, inflammatory resolution, pelvic pain, adhesion-related outcomes and reproductive preservation.Results. The review demonstrated consistent clinical improvements associated with adjunctive distrept-enzymes H46A streptokinase-streptodornase therapy across multiple gynecological settings. Compared with standard management alone, enzymatic therapy was associated with higher rates of complete hematoma resolution, greater reductions in C-reactive protein concentrations, faster functional recovery, improved quality of life, and clinically meaningful reductions in pelvic pain. Improvements in dyspareunia, dysuria and dyschezia were also observed among women with endometriosis-associated symptoms. No evidence suggested an increased frequency of serious adverse events, clinically significant bleeding or treatment discontinuation attributable to therapy. Formal pooled meta-analysis, estimation of between-study heterogeneity and prediction intervals were not appropriate because each outcome was represented by only one independent comparative study.Conclusions. The currently available randomized evidence suggests that distrept-enzymes H46A streptokinase-streptodornase therapy may accelerate postoperative recovery and resolution of pelvic inflammatory disease while supporting preservation of reproductive anatomy and function. Contemporary understanding of fibrinolysis, extracellular DNA, and immunothrombosis provides a strong biological rationale for these clinical observations. Nevertheless, the certainty of evidence remains limited by the small number of independent randomized studies, underscoring the need for multicenter trials.
- Open Access
- 2 July 2026
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 84,p. 27-32
Optimization of management for pregnancy loss: a progesterone support strategy
Pregnancy loss remains one of the most important and challenging medical and social issues in obstetrics. This problem is particularly relevant in Ukraine, where physiological risks are further exacerbated by the adverse effects of chronic war-related stress on women’s reproductive health.Progesterone therapy in early pregnancy is a well-established and effective approach for preventing pregnancy loss. Progesterone is essential for implantation and the maintenance of pregnancy and plays a key role in endometrial receptivity, immune modulation, angiogenesis, and uterine quiescence through its tocolytic effects.A review of current international clinical guidelines and evidence from large randomized clinical trials highlights the need for a differentiated approach to progesterone support. The two main agents used for luteal phase support on the Ukrainian pharmaceutical market are progesterone and dydrogesterone. Owing to its unique retro structure, dydrogesterone exhibits high selectivity for progesterone receptors and significantly greater oral bioavailability than progesterone. Over the past decade, generic formulations of dydrogesterone have been developed, expanding the range of available treatment options on the domestic pharmaceutical market. However, extrapolating pharmacokinetic bioequivalence data from generic products to real-world clinical practice has certain limitations.Despite similarities in key pharmacokinetic parameters with the originator product, differences in excipients and in the technologies used for the complex stereoselective synthesis of dydrogesterone may influence therapeutic outcomes in such a vulnerable patient population as pregnant women.A secondary analysis demonstrated that both originator and generic dydrogesterone provide substantial absolute clinical benefit compared with no treatment (NNT (number needed to treat) ≈ 12 and NNT ≈ 14.5, respectively), whereas the additional benefit of the originator product over the generic corresponds to an NNT of ≈ 70.The assessment of drug interchangeability in obstetrics and reproductive medicine should be based not only on pharmacokinetic studies but also on evidence from clinical trials, pregnancy registries, post-marketing surveillance, and systematic reviews. Definitive confirmation of any differences between originator and generic dydrogesterone requires prospective randomized controlled trials.
- 2 July 2026
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 84,p. 27-32
Open AccessOptimization of management for pregnancy loss: a progesterone support strategy
Pregnancy loss remains one of the most important and challenging medical and social issues in obstetrics. This problem is particularly relevant in Ukraine, where physiological risks are further exacerbated by the adverse effects of chronic war-related stress on women’s reproductive health.Progesterone therapy in early pregnancy is a well-established and effective approach for preventing pregnancy loss. Progesterone is essential for implantation and the maintenance of pregnancy and plays a key role in endometrial receptivity, immune modulation, angiogenesis, and uterine quiescence through its tocolytic effects.A review of current international clinical guidelines and evidence from large randomized clinical trials highlights the need for a differentiated approach to progesterone support. The two main agents used for luteal phase support on the Ukrainian pharmaceutical market are progesterone and dydrogesterone. Owing to its unique retro structure, dydrogesterone exhibits high selectivity for progesterone receptors and significantly greater oral bioavailability than progesterone. Over the past decade, generic formulations of dydrogesterone have been developed, expanding the range of available treatment options on the domestic pharmaceutical market. However, extrapolating pharmacokinetic bioequivalence data from generic products to real-world clinical practice has certain limitations.Despite similarities in key pharmacokinetic parameters with the originator product, differences in excipients and in the technologies used for the complex stereoselective synthesis of dydrogesterone may influence therapeutic outcomes in such a vulnerable patient population as pregnant women.A secondary analysis demonstrated that both originator and generic dydrogesterone provide substantial absolute clinical benefit compared with no treatment (NNT (number needed to treat) ≈ 12 and NNT ≈ 14.5, respectively), whereas the additional benefit of the originator product over the generic corresponds to an NNT of ≈ 70.The assessment of drug interchangeability in obstetrics and reproductive medicine should be based not only on pharmacokinetic studies but also on evidence from clinical trials, pregnancy registries, post-marketing surveillance, and systematic reviews. Definitive confirmation of any differences between originator and generic dydrogesterone requires prospective randomized controlled trials.
- Open Access
- 14 May 2026
- Published by Publishing Office TRILIST
- No. 83
Non-hormonal prevention and treatment of genitourinary syndrome of menopause
Objective of the review: to evaluate the clinical efficacy of hyaluronic acid and polycarbophil in the treatment of genitourinary syndrome of menopause (GSM). Materials and methods. A structured literature review was conducted in accordance with the PRISMA 2020 guidelines. The search was performed in MEDLINE (PubMed), EMBASE, and Cochrane Library databases for the period 2000–2025. Analysis of the literature. The analysis demonstrated that both hyaluronic acid and polycarbophil showed statistically significant improvement in GSM symptoms. Most studies reported a reduction in vaginal dryness and dyspareunia intensity (p < 0.001), improvement in quality of life and sexual function scores (p < 0.001), and an increase in vaginal health index values. Comparative studies did not reveal statistically significant differences between hyaluronic acid and polycarbophil, indicating their clinical equivalence in symptomatic management. At the same time, vaginal estrogen therapy demonstrates a more pronounced and sustained effect. A key finding was the high placebo effect observed in studies of vaginal moisturizers, which complicates data interpretation and highlights the need for larger and more standardized studies. Non-hormonal therapies (hyaluronic acid and polycarbophil) provide clinically meaningful relief of GSM symptoms; however, their effect is predominantly symptomatic and is not associated with restoration of the morphological structure of the vaginal epithelium. A major limitation of current research is the discrepancy between subjective and objective outcome measures, which restricts comprehensive evaluation of therapeutic efficacy. Conclusions. Hyaluronic acid and polycarbophil are effective non-hormonal options for the treatment of mild to moderate GSM, improving symptoms and quality of life. Although vaginal estrogen therapy remains the most effective treatment due to its impact on both symptoms and morphological changes, hyaluronic acid and polycarbophil may be considered first-line therapy in mild to moderate cases, in patients with contraindications to hormones, and in combination regimens to enhance treatment efficacy and adherence.
- 14 May 2026
- Published by Publishing Office TRILIST
- No. 83
Open AccessNon-hormonal prevention and treatment of genitourinary syndrome of menopause
Objective of the review: to evaluate the clinical efficacy of hyaluronic acid and polycarbophil in the treatment of genitourinary syndrome of menopause (GSM). Materials and methods. A structured literature review was conducted in accordance with the PRISMA 2020 guidelines. The search was performed in MEDLINE (PubMed), EMBASE, and Cochrane Library databases for the period 2000–2025. Analysis of the literature. The analysis demonstrated that both hyaluronic acid and polycarbophil showed statistically significant improvement in GSM symptoms. Most studies reported a reduction in vaginal dryness and dyspareunia intensity (p < 0.001), improvement in quality of life and sexual function scores (p < 0.001), and an increase in vaginal health index values. Comparative studies did not reveal statistically significant differences between hyaluronic acid and polycarbophil, indicating their clinical equivalence in symptomatic management. At the same time, vaginal estrogen therapy demonstrates a more pronounced and sustained effect. A key finding was the high placebo effect observed in studies of vaginal moisturizers, which complicates data interpretation and highlights the need for larger and more standardized studies. Non-hormonal therapies (hyaluronic acid and polycarbophil) provide clinically meaningful relief of GSM symptoms; however, their effect is predominantly symptomatic and is not associated with restoration of the morphological structure of the vaginal epithelium. A major limitation of current research is the discrepancy between subjective and objective outcome measures, which restricts comprehensive evaluation of therapeutic efficacy. Conclusions. Hyaluronic acid and polycarbophil are effective non-hormonal options for the treatment of mild to moderate GSM, improving symptoms and quality of life. Although vaginal estrogen therapy remains the most effective treatment due to its impact on both symptoms and morphological changes, hyaluronic acid and polycarbophil may be considered first-line therapy in mild to moderate cases, in patients with contraindications to hormones, and in combination regimens to enhance treatment efficacy and adherence.
- Open Access
- 27 November 2025
- Published by Professional Event, LLC in Reproductive health of woman
- No. 8,p. 122-128
L-arginine in the management of menopausal symptoms: vascular, metabolic, and quality-of-life effects (a systematic literature review)
Menopause is a critical period in a woman’s life, which is accompanied by complex physiological, psycho-emotional, and metabolic changes that significantly affect quality of life. An important pathogenetic mechanism during this period is the development of endothelial dysfunction and the reduction of nitric oxide (NO) bioavailability, which leads to impaired vascular reactivity, increased risk of cardiovascular disease, and intensification of vasomotor symptoms (VMS). L-arginine, as the main substrate for NO synthase, is considered a promising non-hormonal agent for the correction of menopausal disorders, it is able to influence on vascular, metabolic, and sexual function, as well as the overall well-being of women in peri- and postmenopause. The aim of this work was to summarize current data on the role and clinical effectiveness of L-arginine in the management of menopausal symptoms.A systematic analytical review of clinical studies which were published in international databases (PubMed, Scopus, Cochrane Library, Web of Science) and local sources from 2010 to 2025 was conducted. The analysis included randomized controlled trials and large prospective cohort studies that evaluated the effectiveness of oral L-arginine of the following indications: reduction of the frequency and intensity of VMS, correction of menopausal endotheliopathy, improvement of sexual function, and its impact on microcirculation, lipid metabolism, glycemic markers, and the severity of climacteric syndrome (Kupperman index, Menopause-Specific Quality of Life Questionnaire – MENQOL, The Short Form-36 Health Survey – SF-36).The results of the analysis indicate that L-arginine contributes to a significant improvement in endothelial function, reduction of triglycerides, total cholesterol, low-density lipoproteins, and fasting glucose. In most studies, a statistically significant decrease in the Kupperman index and the frequency of VMS was observed, confirming its clinical effectiveness in correction of climacteric manifestations. Data on improvements in quality of life according to MENQOL and SF-36 scales remain heterogeneous, with the most pronounced effects reported in studies of combined nutrient supplements. At the same time, L-arginine is characterized by good tolerability and a favorable safety profile, with adverse effects limited to mild gastrointestinal symptoms.Thus, L-arginine is a promising non-hormonal agent in the management of menopausal symptoms due to its effect on the “L-arginine – NO – cyclic guanosine monophosphate – vasodilation” pathway. Its use improves vascular and metabolic parame-ters, reduces the severity of climacteric manifestations, and may positively influence sexual function and the overall well-being of women in peri- and postmenopause. Further large-scale randomized trials are needed to confirm these findings, standardize dosages, and determine the long-term effects of therapy.
- 27 November 2025
- Published by Professional Event, LLC in Reproductive health of woman
- No. 8,p. 122-128
Open AccessL-arginine in the management of menopausal symptoms: vascular, metabolic, and quality-of-life effects (a systematic literature review)
Menopause is a critical period in a woman’s life, which is accompanied by complex physiological, psycho-emotional, and metabolic changes that significantly affect quality of life. An important pathogenetic mechanism during this period is the development of endothelial dysfunction and the reduction of nitric oxide (NO) bioavailability, which leads to impaired vascular reactivity, increased risk of cardiovascular disease, and intensification of vasomotor symptoms (VMS). L-arginine, as the main substrate for NO synthase, is considered a promising non-hormonal agent for the correction of menopausal disorders, it is able to influence on vascular, metabolic, and sexual function, as well as the overall well-being of women in peri- and postmenopause. The aim of this work was to summarize current data on the role and clinical effectiveness of L-arginine in the management of menopausal symptoms.A systematic analytical review of clinical studies which were published in international databases (PubMed, Scopus, Cochrane Library, Web of Science) and local sources from 2010 to 2025 was conducted. The analysis included randomized controlled trials and large prospective cohort studies that evaluated the effectiveness of oral L-arginine of the following indications: reduction of the frequency and intensity of VMS, correction of menopausal endotheliopathy, improvement of sexual function, and its impact on microcirculation, lipid metabolism, glycemic markers, and the severity of climacteric syndrome (Kupperman index, Menopause-Specific Quality of Life Questionnaire – MENQOL, The Short Form-36 Health Survey – SF-36).The results of the analysis indicate that L-arginine contributes to a significant improvement in endothelial function, reduction of triglycerides, total cholesterol, low-density lipoproteins, and fasting glucose. In most studies, a statistically significant decrease in the Kupperman index and the frequency of VMS was observed, confirming its clinical effectiveness in correction of climacteric manifestations. Data on improvements in quality of life according to MENQOL and SF-36 scales remain heterogeneous, with the most pronounced effects reported in studies of combined nutrient supplements. At the same time, L-arginine is characterized by good tolerability and a favorable safety profile, with adverse effects limited to mild gastrointestinal symptoms.Thus, L-arginine is a promising non-hormonal agent in the management of menopausal symptoms due to its effect on the “L-arginine – NO – cyclic guanosine monophosphate – vasodilation” pathway. Its use improves vascular and metabolic parame-ters, reduces the severity of climacteric manifestations, and may positively influence sexual function and the overall well-being of women in peri- and postmenopause. Further large-scale randomized trials are needed to confirm these findings, standardize dosages, and determine the long-term effects of therapy.
- Open Access
- 30 September 2025
- Published by Professional Event, LLC in Reproductive health of woman
- No. 6,p. 53-64
Modern strategies for the prevention and treatment of human papillomavirus
Human papillomavirus (HPV) remains one of the most prevalent sexually transmitted infections worldwide, with high-risk oncogenic types being closely associated with the development of cervical, anogenital, and oropharyngeal cancers. Despite the availability of effective prophylactic vaccines, the widespread persistence of HPV infection, insufficient immunization coverage in certain regions, and the lack of specific antiviral therapy underscore the need to improve strategies for prevention and treatment.To analyze current approaches to the prevention and treatment of HPV infection with an emphasis on the effectiveness of vaccination, therapeutic interventions, and the potential role of interferon therapy – particularly interferon-α-2b – as a promising immunomodulatory agent.This article presents an analytical review of up-to-date publications, clinical guidelines, and recommendations from World Health Organization, Centers for Disease Control and Prevention, and European Centre for Disease Prevention and Control, along with results from randomized clinical trials regarding HPV prevention and treatment. The evidence base for vaccination, local destructive methods, immunostimulatory therapy, and interferon use is summarized and critically evaluated.Prophylactic vaccination remains the most effective tool in preventing infections caused by high-risk HPV types and the associated precancerous lesions. In the treatment of HPV-induced changes, surgical and destructive methods, immunomodulatory agents, as well as experimental therapeutic vaccines that are in the final stages of clinical trials are used. Interferon-α-2b as an immunomodulator has demonstrated the ability to stimulate antiviral immune responses, promote the regression of cervical intraepithelial neoplasia, and reduce recurrence rates in patients with persistent HPV infection.Modern strategies for HPV management should be comprehensive, combining vaccination, regular screening, timely lesion detection, and personalized treatment approaches, including immunomodulatory therapies. Further clinical studies on the use of interferon-α-2b are warranted to expand therapeutic options for patients with persistent HPV-related disease.
- 30 September 2025
- Published by Professional Event, LLC in Reproductive health of woman
- No. 6,p. 53-64
Open AccessModern strategies for the prevention and treatment of human papillomavirus
Human papillomavirus (HPV) remains one of the most prevalent sexually transmitted infections worldwide, with high-risk oncogenic types being closely associated with the development of cervical, anogenital, and oropharyngeal cancers. Despite the availability of effective prophylactic vaccines, the widespread persistence of HPV infection, insufficient immunization coverage in certain regions, and the lack of specific antiviral therapy underscore the need to improve strategies for prevention and treatment.To analyze current approaches to the prevention and treatment of HPV infection with an emphasis on the effectiveness of vaccination, therapeutic interventions, and the potential role of interferon therapy – particularly interferon-α-2b – as a promising immunomodulatory agent.This article presents an analytical review of up-to-date publications, clinical guidelines, and recommendations from World Health Organization, Centers for Disease Control and Prevention, and European Centre for Disease Prevention and Control, along with results from randomized clinical trials regarding HPV prevention and treatment. The evidence base for vaccination, local destructive methods, immunostimulatory therapy, and interferon use is summarized and critically evaluated.Prophylactic vaccination remains the most effective tool in preventing infections caused by high-risk HPV types and the associated precancerous lesions. In the treatment of HPV-induced changes, surgical and destructive methods, immunomodulatory agents, as well as experimental therapeutic vaccines that are in the final stages of clinical trials are used. Interferon-α-2b as an immunomodulator has demonstrated the ability to stimulate antiviral immune responses, promote the regression of cervical intraepithelial neoplasia, and reduce recurrence rates in patients with persistent HPV infection.Modern strategies for HPV management should be comprehensive, combining vaccination, regular screening, timely lesion detection, and personalized treatment approaches, including immunomodulatory therapies. Further clinical studies on the use of interferon-α-2b are warranted to expand therapeutic options for patients with persistent HPV-related disease.
- Open Access
- 30 May 2025
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 77,p. 57-63
The assessment of anti-recurrence efficacy of Prodexin in the treatment of bacterial vaginosis
Background. Bacterial vaginosis (BV) remains the most common vaginal infection globally, often exhibiting high recurrence rates despite standard antimicrobial therapy. The persistence of BV is frequently attributed to polymicrobial biofilms and altered vaginal microbiota, which challenge conventional treatment efficacy. Objective of the study: To assess the long-term anti-relapse effectiveness and patient adherence associated with Prodexyn (a combination of octenidine dihydrochloride and dexpanthenol) compared to standard topical antimicrobial agents in women with a history of recurrent BV. Materials and methods. In this prospective comparative study (phase II of the PRO-BAVAG project), 119 women with a previous history of BV recurrence were enrolled and stratified based on previous treatment regimens. Participants received either Prodexyn (n = 52), ternidazole (n = 41), or metronidazole (n = 26). Recurrence was evaluated using clinical symptoms and Hay-Ison criteria at 3, 6, and 9 months. Treatment adherence was measured using the MMAS-8 scale. Results. No recurrences were recorded in the Prodexyn group after 3 months. At 6 and 9 months, the recurrence rate remained significantly lower in the Prodexyn group compared to both comparison groups (p < 0.05). Additionally, high adherence to therapy was noted in 92.3% of Prodexyn users, significantly outperforming adherence in the metronidazole and ternidazole groups (p < 0.01). The probable reason for the better anti-relapse effect of Prodexin can be considered the biofilm-targeting effect of octenidine and its lactoflora preserving effect. Conclusions. Prodexyn demonstrated superior long-term efficacy in preventing BV recurrence and showed high patient adherence. Its dual action (targeting vaginal biofilms and preserving lactoflora) suggests a promising alternative to traditional antimicrobial therapies. Further studies are needed to confirm its biofilm-disruptive mechanisms and define optimal treatment durations.
- 30 May 2025
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 77,p. 57-63
Open AccessThe assessment of anti-recurrence efficacy of Prodexin in the treatment of bacterial vaginosis
Background. Bacterial vaginosis (BV) remains the most common vaginal infection globally, often exhibiting high recurrence rates despite standard antimicrobial therapy. The persistence of BV is frequently attributed to polymicrobial biofilms and altered vaginal microbiota, which challenge conventional treatment efficacy. Objective of the study: To assess the long-term anti-relapse effectiveness and patient adherence associated with Prodexyn (a combination of octenidine dihydrochloride and dexpanthenol) compared to standard topical antimicrobial agents in women with a history of recurrent BV. Materials and methods. In this prospective comparative study (phase II of the PRO-BAVAG project), 119 women with a previous history of BV recurrence were enrolled and stratified based on previous treatment regimens. Participants received either Prodexyn (n = 52), ternidazole (n = 41), or metronidazole (n = 26). Recurrence was evaluated using clinical symptoms and Hay-Ison criteria at 3, 6, and 9 months. Treatment adherence was measured using the MMAS-8 scale. Results. No recurrences were recorded in the Prodexyn group after 3 months. At 6 and 9 months, the recurrence rate remained significantly lower in the Prodexyn group compared to both comparison groups (p < 0.05). Additionally, high adherence to therapy was noted in 92.3% of Prodexyn users, significantly outperforming adherence in the metronidazole and ternidazole groups (p < 0.01). The probable reason for the better anti-relapse effect of Prodexin can be considered the biofilm-targeting effect of octenidine and its lactoflora preserving effect. Conclusions. Prodexyn demonstrated superior long-term efficacy in preventing BV recurrence and showed high patient adherence. Its dual action (targeting vaginal biofilms and preserving lactoflora) suggests a promising alternative to traditional antimicrobial therapies. Further studies are needed to confirm its biofilm-disruptive mechanisms and define optimal treatment durations.
- Open Access
- 31 March 2025
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 76,p. 34-38
Successful pregnancy: simply about the complicated
Progesterone is a key hormone essential for maintaining pregnancy. Its deficiency can lead to the risk of miscarriage, recurrent pregnancy loss, and unsuccessful attempts at in vitro fertilization. In clinical practice, progestogens are used for luteal phase support, particularly in women with corpus luteum insufficiency or in assisted reproductive technologies cycles.After the synthetic progestogen 17-hydroxyprogesterone caproate was withdrawn from the pharmaceutical market due to low efficacy and multiple side effects, only two effective agents remain in obstetrics and reproductive medicine – progesterone and dydrogesterone.Dydrogesterone is a synthetic analog of natural progesterone with high oral bioavailability, making it a convenient alternative to other forms of progestogens. It selectively binds to progesterone receptors, ensuring stable endometrial support and promoting early pregnancy maintenance. Unlike some other progestogens, dydrogesterone has no androgenic, estrogenic, or glucocorticoid effects, which contributes to its better tolerability.The evidence base supporting dydrogesterone’s efficacy includes numerous randomized controlled trials, particularly LOTUS I and LOTUS II, which demonstrated that oral dydrogesterone is as effective as vaginal progesterone for luteal phase support at in vitro fertilization cycles. Additionally, multiple meta-analyses confirm that dydrogesterone use in the first trimester significantly reduces the risk of miscarriage, and over 70 studies have confirmed the high efficacy and safety of its molecule for both women and fetuses.The safety of dydrogesterone is particularly important. The international expert group on the safety of progestogens in early pregnancy REASSURE concluded that there is currently no basis for making statements about a causal relationship between the use of dydrogesterone in the first trimester and the risk of congenital malformations.Thus, due to its proven efficacy and excellent safety profile, supported by over 60 years of clinical use, dydrogesterone is the optimal choice for luteal phase support in both natural cycles and assisted reproductive technologies.
- 31 March 2025
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 76,p. 34-38
Open AccessSuccessful pregnancy: simply about the complicated
Progesterone is a key hormone essential for maintaining pregnancy. Its deficiency can lead to the risk of miscarriage, recurrent pregnancy loss, and unsuccessful attempts at in vitro fertilization. In clinical practice, progestogens are used for luteal phase support, particularly in women with corpus luteum insufficiency or in assisted reproductive technologies cycles.After the synthetic progestogen 17-hydroxyprogesterone caproate was withdrawn from the pharmaceutical market due to low efficacy and multiple side effects, only two effective agents remain in obstetrics and reproductive medicine – progesterone and dydrogesterone.Dydrogesterone is a synthetic analog of natural progesterone with high oral bioavailability, making it a convenient alternative to other forms of progestogens. It selectively binds to progesterone receptors, ensuring stable endometrial support and promoting early pregnancy maintenance. Unlike some other progestogens, dydrogesterone has no androgenic, estrogenic, or glucocorticoid effects, which contributes to its better tolerability.The evidence base supporting dydrogesterone’s efficacy includes numerous randomized controlled trials, particularly LOTUS I and LOTUS II, which demonstrated that oral dydrogesterone is as effective as vaginal progesterone for luteal phase support at in vitro fertilization cycles. Additionally, multiple meta-analyses confirm that dydrogesterone use in the first trimester significantly reduces the risk of miscarriage, and over 70 studies have confirmed the high efficacy and safety of its molecule for both women and fetuses.The safety of dydrogesterone is particularly important. The international expert group on the safety of progestogens in early pregnancy REASSURE concluded that there is currently no basis for making statements about a causal relationship between the use of dydrogesterone in the first trimester and the risk of congenital malformations.Thus, due to its proven efficacy and excellent safety profile, supported by over 60 years of clinical use, dydrogesterone is the optimal choice for luteal phase support in both natural cycles and assisted reproductive technologies.
- Open Access
- 30 September 2024
- Published by Publishing Office TRILIST
- No. 73
Resolution of the I Ukrainian forum on miscarriages
Today, there is an urgent need to develop and implement a regulatory document on abortion. This is due to the catastrophic state of reproduction of the Ukrainian population – the annual decrease in the number of labor, birth rates and the demographic crisis in Ukraine in general. Pregnancy loss not only causes obstetric complications, but also causes significant damage of the mental health of the woman and her partner, including depression and post-traumatic stress disorder.This resolution is a joint position of the leading specialists of Ukraine on the issue of miscarriages based on domestic experience, results of randomized controlled trials and meta-analyses, as well as clinical recommendations of scientific societies of the world. The presented information is designed to help improve clinical approaches to the management of miscarriage in today’s conditions, in order to save every pregnancy and to not lose a baby.During the Forum, the practical issues of diagnosis and treatment of miscarriage, modern management of threatened and habitual miscarriage, hormonal support of pregnant women and the use of progestogens, the influence of the first half of pregnancy on the birth of a healthy child, the impact of liver diseases on the choice of therapy in a pregnant woman, and others issues were considered.World clinical experience has convincingly proven the high effectiveness of progestogens in the therapy of threatened and repeated miscarriages. However, not all progestogens are equally effective in reducing the risk of miscarriage and live birth in case of threatened miscarriage. Micronized progesterone and dydrogesterone are the most effective. Dydrogesterone differs from progesterone in its mechanism of action and affinity for progesterone receptors. A strong evidence base has been accumulated about a high profile of effectiveness and a low frequency of maternal and fetal complications for dydrogesterone, the use of which is approved by leading foreign associations.Drug interactions and their effects on the liver should also be taken into account. Drugs that are indicated for pregnant women should be prescribed in the smallest therapeutic dose, which should be effective.
- 30 September 2024
- Published by Publishing Office TRILIST
- No. 73
Open AccessResolution of the I Ukrainian forum on miscarriages
Today, there is an urgent need to develop and implement a regulatory document on abortion. This is due to the catastrophic state of reproduction of the Ukrainian population – the annual decrease in the number of labor, birth rates and the demographic crisis in Ukraine in general. Pregnancy loss not only causes obstetric complications, but also causes significant damage of the mental health of the woman and her partner, including depression and post-traumatic stress disorder.This resolution is a joint position of the leading specialists of Ukraine on the issue of miscarriages based on domestic experience, results of randomized controlled trials and meta-analyses, as well as clinical recommendations of scientific societies of the world. The presented information is designed to help improve clinical approaches to the management of miscarriage in today’s conditions, in order to save every pregnancy and to not lose a baby.During the Forum, the practical issues of diagnosis and treatment of miscarriage, modern management of threatened and habitual miscarriage, hormonal support of pregnant women and the use of progestogens, the influence of the first half of pregnancy on the birth of a healthy child, the impact of liver diseases on the choice of therapy in a pregnant woman, and others issues were considered.World clinical experience has convincingly proven the high effectiveness of progestogens in the therapy of threatened and repeated miscarriages. However, not all progestogens are equally effective in reducing the risk of miscarriage and live birth in case of threatened miscarriage. Micronized progesterone and dydrogesterone are the most effective. Dydrogesterone differs from progesterone in its mechanism of action and affinity for progesterone receptors. A strong evidence base has been accumulated about a high profile of effectiveness and a low frequency of maternal and fetal complications for dydrogesterone, the use of which is approved by leading foreign associations.Drug interactions and their effects on the liver should also be taken into account. Drugs that are indicated for pregnant women should be prescribed in the smallest therapeutic dose, which should be effective.
- Open Access
- 30 September 2024
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 73,p. 60-66
Features of correction of metabolic disorders in women with polycystic ovary syndrome
Background. A significant proportion of couples worldwide suffer from infertility associated with polycystic ovary syndrome (PCOS). PCOS is characterized by increased androgen synthesis in the theca cells of the ovaries, hyperandrogenemia and ovarian dysfunction in women. Most of the clinical symptoms and altered levels of blood biomarkers in PCOS patients point to metabolic dysregulation and adaptive changes as key underlying mechanisms of disease development. Since the liver is the metabolic center of the body and participates in steroid-hormonal detoxification, pathological changes in it can contribute to endocrine disorders through the liver-ovary axis. Of particular interest is hyperglycemia, changes in secretory proteins of the liver and insulin sensitivity, which affect the maturation of ovarian follicles and can potentially lead to female infertility.Objective of the review: to provide an understanding of the new metabolic mechanisms underlying PCOS, which lead to the disease and its exacerbation, as well as to summarize therapeutic approaches to the correction of PCOS complications, in particular, liver function disorders using the drug Hepatomunil. Analysis of literary data. This review presents the relationship and underlying mechanistic basis between PCOS and metabolic disorders in women by summarizing the main pathologic features of the disease. Most symptoms of PCOS are associated with insulin resistance, type II diabetes, decreased levels of sex hormone-binding globulin, increased levels of alanine aminotransferase and aspartate aminotransferase, which may indicate liver dysfunction. The metabolic profile and function of the ovaries can be affected by any pathological changes in the levels of systemic metabolism and/or in peripheral organs, in particular the liver, which serves as the metabolic center of the body, mediating its effects through the liver-ovary axis.Conclusions. Despite the lack of a clear protocol for the correction of liver function disorders and non-alcoholic fatty liver disease in PCOS patients, lifestyle modification should be the basis. Drugs that improve metabolism, as well as hepatoprotectors with immunomodulatory properties (the drug Hepatomunil) may have positive prospects for use.
- 30 September 2024
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 73,p. 60-66
Open AccessFeatures of correction of metabolic disorders in women with polycystic ovary syndrome
Background. A significant proportion of couples worldwide suffer from infertility associated with polycystic ovary syndrome (PCOS). PCOS is characterized by increased androgen synthesis in the theca cells of the ovaries, hyperandrogenemia and ovarian dysfunction in women. Most of the clinical symptoms and altered levels of blood biomarkers in PCOS patients point to metabolic dysregulation and adaptive changes as key underlying mechanisms of disease development. Since the liver is the metabolic center of the body and participates in steroid-hormonal detoxification, pathological changes in it can contribute to endocrine disorders through the liver-ovary axis. Of particular interest is hyperglycemia, changes in secretory proteins of the liver and insulin sensitivity, which affect the maturation of ovarian follicles and can potentially lead to female infertility.Objective of the review: to provide an understanding of the new metabolic mechanisms underlying PCOS, which lead to the disease and its exacerbation, as well as to summarize therapeutic approaches to the correction of PCOS complications, in particular, liver function disorders using the drug Hepatomunil. Analysis of literary data. This review presents the relationship and underlying mechanistic basis between PCOS and metabolic disorders in women by summarizing the main pathologic features of the disease. Most symptoms of PCOS are associated with insulin resistance, type II diabetes, decreased levels of sex hormone-binding globulin, increased levels of alanine aminotransferase and aspartate aminotransferase, which may indicate liver dysfunction. The metabolic profile and function of the ovaries can be affected by any pathological changes in the levels of systemic metabolism and/or in peripheral organs, in particular the liver, which serves as the metabolic center of the body, mediating its effects through the liver-ovary axis.Conclusions. Despite the lack of a clear protocol for the correction of liver function disorders and non-alcoholic fatty liver disease in PCOS patients, lifestyle modification should be the basis. Drugs that improve metabolism, as well as hepatoprotectors with immunomodulatory properties (the drug Hepatomunil) may have positive prospects for use.
- Open Access
- 25 September 2024
- Published by Vinnytsia National Pyrogov Memorial Medical University in Reports of Vinnytsia National Medical University
- Vol. 28 (3) , 511-519
Kidney stone disease and pregnancy: the features of the obstetric clinical management
Annotation. The article presents the results of a structured review of ukranian and foreign literary sources in the search databases PUBMED, EMBASE, Google Scholar, UpToDate, Web of Science, Scopus regarding the problem of urolithiasis during pregnancy over the past 15 years. The search was carried out using the terms “pregnancy”, “urolithiasis and pregnancy”, “renal colic” separately and in combination with “stone”, “kidney stone”, “ultrasound examination”, “magnetic resonance imaging”, “computed tomography”, “percutaneous nephrostomy”, “ureteral stent”, “ureteroscopy". The additional publications were identified by reviewing the reference lists of relevant articles identified in the first literature search. A total of 47 articles were included. There were found that this pathology is the most common non-obstetrical cause of hospitalization of pregnant women and is diagnosed in 80-90% in the II-III trimesters, when the disease has a course with the most extensive clinical scenario. Ultrasound remains the recommended first-line imaging option. Complicated cases, such as suspected infected obstructed system, require urgent decompression such as in the form of percutaneous nephrostomy. This review highlights conservative treatment that have been considered safe for use during pregnancy. If surgery is indicated, the evidence supports that ureteroscopy is a safe option if the infection has been treated. Ureteroscopy may offer definitive removal of the stone(s) and may be less burdensome in terms of unpleasant symptoms compared to a permanent ureteral stent or nephrostomy, which also require regular replacement due to the high propensity for encrustation during pregnancy. The approach to the management of nephrolithiasis during pregnancy has certain difficulties, since the use of diagnostic and therapeutic methods is limited. Management of this category of patients always requires a multidisciplinary approach, depends on the presence of complications and requires careful observation of patients throughout pregnancy.
- 25 September 2024
- Published by Vinnytsia National Pyrogov Memorial Medical University in Reports of Vinnytsia National Medical University
- Vol. 28 (3) , 511-519
Open AccessKidney stone disease and pregnancy: the features of the obstetric clinical management
Annotation. The article presents the results of a structured review of ukranian and foreign literary sources in the search databases PUBMED, EMBASE, Google Scholar, UpToDate, Web of Science, Scopus regarding the problem of urolithiasis during pregnancy over the past 15 years. The search was carried out using the terms “pregnancy”, “urolithiasis and pregnancy”, “renal colic” separately and in combination with “stone”, “kidney stone”, “ultrasound examination”, “magnetic resonance imaging”, “computed tomography”, “percutaneous nephrostomy”, “ureteral stent”, “ureteroscopy". The additional publications were identified by reviewing the reference lists of relevant articles identified in the first literature search. A total of 47 articles were included. There were found that this pathology is the most common non-obstetrical cause of hospitalization of pregnant women and is diagnosed in 80-90% in the II-III trimesters, when the disease has a course with the most extensive clinical scenario. Ultrasound remains the recommended first-line imaging option. Complicated cases, such as suspected infected obstructed system, require urgent decompression such as in the form of percutaneous nephrostomy. This review highlights conservative treatment that have been considered safe for use during pregnancy. If surgery is indicated, the evidence supports that ureteroscopy is a safe option if the infection has been treated. Ureteroscopy may offer definitive removal of the stone(s) and may be less burdensome in terms of unpleasant symptoms compared to a permanent ureteral stent or nephrostomy, which also require regular replacement due to the high propensity for encrustation during pregnancy. The approach to the management of nephrolithiasis during pregnancy has certain difficulties, since the use of diagnostic and therapeutic methods is limited. Management of this category of patients always requires a multidisciplinary approach, depends on the presence of complications and requires careful observation of patients throughout pregnancy.